Sartorius Stedim Biotech releases Universal Registration Document 2025
16.02.2026 - 09:13:53 | dgap.de| Sartorius Stedim Biotech SA / Key word(s): Annual Results 16-Feb-2026 / 09:13 CET/CEST Aubagne, France | February 16, 2026 Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2025 including the Annual Financial Report. The document is available at the following link: https://www.sartorius.com/urd2025 Financial calendar March 24, 2026 | Annual Shareholders' Meeting April 23, 2026 | Publication of the first quarter results for January to March 2026 July 23, 2026 | Publication of half-year results for January to June 2026 October 22, 2026 | Publication of nine-month results January to September 2026 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3 billion euros, according to preliminary figures. Currently, more than 10,200 employees are working for customers around the globe. Visit our newsroom and follow us on LinkedIn. Contact Verena Sattel External Communications +49 551 308 9261 verena.sattel@sartorius.com Attachment File: | Media Release Dissemination of a Financial Wire News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. View original content: EQS News |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2275078 |
| End of Announcement - EQS News Service | |
| |
So schätzen die Börsenprofis Sartorius Stedim Biotech SA Aktien ein!
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
FR0013154002 | SARTORIUS STEDIM BIOTECH SA | boerse | 68584668 |

